EFFECT OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS ON LIPID LEVELS IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS

Aim: This study aimed to examine the effects of sodium glucose cotransporter 2 inhibitors (SGLT-2i) on lipid levels at 12 weeks follow-up in newly diagnosed hypertensive (NDHT) patients with type diabetes mellitus (T2DM). Methodsː retrospective study, 236 NDHT T2DM were included. The SGLT-2i group consisted who received (empagliflozin or dapagliflozin) addition stable triple combination treatment. control was selected over did not receive and matched terms baseline risk factors by propensity score. laboratory findings compared retrospectively time diagnosis (baseline) 12-month followup. Resultsː decrease fasting blood hemoglobin A1C higher than group. Although both groups similar antihypertensive therapy, improvement profile Glycemic side empagliflozin dapagliflozin groups. However, greater profiles detected users. Conclusionsː In T2DM, SGLT2i treatment management cases where glycemic is achieved associated more without significant effects. various agents this may be different.